Kevin Bowman

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

Xiangdong Liu, Niu Shin, Holly K. Koblish et al. · Blood · 2010 · 559 citations · Full text

Medicine, Immunology, Oncology +14

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

Gregory L. Beatty, Peter J. O’Dwyer, Jason Clark et al. · Clinical Cancer Research · 2017 · 318 citations · Full text

Medicine, Oncology, Pharmacology +14

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

Eddy W. Yue, Richard Sparks, Padmaja Polam et al. · ACS Medicinal Chemistry Letters · 2017 · 296 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +8

Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors

Holly K. Koblish, Michael Hansbury, Kevin Bowman et al. · Molecular Cancer Therapeutics · 2010 · 245 citations · Full text

Medicine, Oncology, Pharmacology +13

Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model

Eddy W. Yue, Brent Douty, Brian Wayland et al. · Journal of Medicinal Chemistry · 2009 · 217 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9